纳米比亚启动抗逆转录病毒治疗的成人中治疗前HIV耐药情况
2015-16年在纳米比亚开展全国代表性横断面调查,对381份启动标准化一线抗逆转录病毒治疗(ART)的成人血样进行基因型耐药检测,治疗前HIV耐药(PDR)患病率为12.7%,其中非核苷类逆转录酶抑制剂(NNRTI)耐药最常见(11.9%)。有既往抗逆转录病毒药物暴露者PDR高于无暴露者(30.5% vs 9.6%,患病率比=3.17,P<0.01)。
要点
- 纳米比亚启动一线ART成人中PDR总体患病率>10%,NNRTI耐药最常见(11.9%)。
- 有既往抗逆转录病毒药物暴露者PDR为30.5%,无暴露者为9.6%(患病率比=3.17,P<0.01)。
- 作者认为应考虑引入非NNRTI为基础的一线ART方案。
核心结论
- 本次调查显示纳米比亚启动ART的成人中PDR总体患病率>10%,有既往抗逆转录病毒药物暴露者PDR更高。
- 作者认为应考虑引入非NNRTI为基础的一线ART方案,以最大化ART获益并减少HIV耐药的出现。
研究设计与样本
- 2015-16年开展全国代表性横断面调查,纳入≥18岁同意参加并启动标准化一线ART的成人患者。
- 采集干血斑样本进行耐药检测,共381份标本成功完成基因型检测。
- PDR定义为根据2014年WHO成人启动ART时HIV耐药监测标准,导致低、中、高水平抗逆转录病毒药物耐药的突变。
- 结果经加权以代表全国情况。
主要发现
- 381份标本中144份(36.6%)检出HIV耐药,其中54份(12.7%)为PDR。
- NNRTI耐药最常见,占11.9%。
- 有既往抗逆转录病毒药物暴露者PDR为30.5%,无暴露者为9.6%(患病率比=3.17;P<0.01)。
关键数值与推荐
- PDR定义采用2014年WHO成人启动ART时HIV耐药监测标准,即导致低、中、高水平耐药的突变。
- PDR总体患病率为12.7%,NNRTI耐药为11.9%。
- 有既往抗逆转录病毒药物暴露者PDR为30.5%,无暴露者为9.6%(患病率比=3.17;P<0.01)。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Continued use of standardized, first-line ART containing NNRTIs and NRTIs may contribute to ongoing emergence of HIV drug resistance (HIVDR) in Namibia. METHODS: A nationally representative cross-sectional survey was conducted during 2015-16 to estimate the prevalence of significant pretreatment HIV drug resistance (PDR) and viral load (VL) suppression rates 6-12 months after initiating standardized first-line ART. Consenting adult patients (≥18 years) initiating ART were interviewed about prior antiretroviral drug (ARV) exposure and underwent resistance testing using dried blood spot samples. PDR was defined as mutations causing low-, intermediate- and high-level resistance to ARVs according to the 2014 WHO Surveillance of HIV Drug Resistance in Adults Initiating ART. The prevalence of PDR was described by patient characteristics, ARV exposure and VL results. Results were weighted to be nationally representative. RESULTS: Successful genotyping was performed for 381 specimens; 144 (36.6%) specimens demonstrated HIVDR, of which 54 (12.7%) demonstrated PDR. Resistance to NNRTIs was most prevalent (11.9%). PDR was higher in patients with previous ARV exposure compared with no exposure (30.5% versus 9.6%) (prevalence ratio = 3.17; P < 0.01). CONCLUSIONS: This survey demonstrated overall PDR at >10% among adults initiating ART in Namibia. Patients with prior ARV exposure had higher rates of PDR. Introducing a non-NNRTI-based regimen for first-line ART should be considered to maximize benefit of ART and minimize the emergence of HIVDR.
引用
- Taffa N, Roscoe C, Sawadogo S, et al. Pretreatment HIV drug resistance among adults initiating ART in Namibia. J Antimicrob Chemother. 2018. PMID: 30137412. doi:10.1093/jac/dky278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。